Oral cancer prevention advances with a translational trial of green tea.
This perspective on Tsao et al. (beginning on p. 931 in this issue of the journal) discusses green tea extract, which was shown for the first time to have dose-dependent effects in a clinical chemopreventive setting (oral premalignant lesions). This translational trial provides important data on angiogenesis and other biomarkers on which to base future clinical research, which should include trials of green tea extract or polyphenols combined with other natural or synthetic compounds to enhance chemopreventive effects.
Shin
Dong M
DM
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA. dmshin@emory.edu
D006801:Humans; D009062:Mouth Neoplasms / Q000517:prevention & control*; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D011230:Precancerous Conditions / Q000517:prevention & control*; D013662:Tea; D016896:Treatment Outcome
D010936:Plant Extracts; D013662:Tea